XML 47 R15.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Balance Sheet Account Details | 12 Months Ended
--- | ---
Dec. 31, 2019
Other Balance Sheet Details [Abstract] |
Balance Sheet Account Details | Balance Sheet Account Details Short-term Investments The following table summarizes the various investment categories at December 31, 2019 and 2018 (in thousands):
| Cost |  | Gross unrealized gains |  | Gross unrealized losses |  | Estimated fair value
December 31, 2019 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Bank deposits | $ | 411,690 |  |  | $ | 188 |  |  | $ | (3) |  |  | $ | 411,875 |
Corporate bonds | 63,818 |  |  | 161 |  |  | — |  |  | 63,979 |
Corporate equity securities | 4,506 |  |  | 416 |  |  | (1,850) |  |  | 3,072 |
Commercial paper | 210,525 |  |  | 43 |  |  | (16) |  |  | 210,552 |
Warrants | — |  |  | 125 |  |  | — |  |  | 125 |
Mutual fund | 250,635 |  |  | — |  |  | (249) |  |  | 250,386 |
| $ | 941,174 |  |  | $ | 933 |  |  | $ | (2,118) |  |  | $ | 939,989 |
December 31, 2018 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Bank deposits | $ | 311,066 |  |  | $ | 26 |  |  | $ | (29) |  |  | $ | 311,063 |
Corporate bonds | 53,223 |  |  | 1 |  |  | (45) |  |  | 53,179 |
Corporate equity securities | 135 |  |  | 1,191 |  |  | — |  |  | 1,326 |
Commercial paper | 225,731 |  |  | 8 |  |  | (76) |  |  | 225,663 |
U.S. Government bonds | 7,982 |  |  | — |  |  | (9) |  |  | 7,973 |
Municipal bonds | 2,017 |  |  | — |  |  | (4) |  |  | 2,013 |
| $ | 600,154 |  |  | $ | 1,226 |  |  | $ | (163) |  |  | $ | 601,217 |
Property and equipment are stated at cost and consists of the following (in thousands):
| December 31, |  |
| 2019 |  | 2018
Lab and office equipment | $ | 6,307 |  |  | $ | 4,183 |
Leasehold improvements | 2,729 |  |  | 2,418 |
Computer equipment and software | 999 |  |  | 936 |
| 10,035 |  |  | 7,537 |
Less accumulated depreciation and amortization | (2,850) |  |  | (2,165) |
| $ | 7,185 |  |  | $ | 5,372 |
Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $1.5 million, $0.9 million, and $0.4 million was recognized for the twelve months ended ended December 31, 2019, 2018, and 2017, respectively, and was included in operating expenses. Goodwill and identifiable intangible assets consist of the following (in thousands):
| As of December 31, |  |
| 2019 |  | 2018
Indefinite lived intangible assets |  |  |
Goodwill | $ | 95,229 |  |  | $ | 86,646 |
Definite lived intangible assets |  |  |
Complete technology | 242,813 |  |  | 235,413 |
Less: Accumulated amortization(1) | (50,203) |  |  | (35,070) |
Trade name | 2,642 |  |  | 2,642 |
Less: Accumulated amortization | (1,180) |  |  | (1,048) |
Customer relationships | 29,600 |  |  | 29,600 |
Less: Accumulated amortization | (13,224) |  |  | (11,744) |
Total goodwill and other identifiable intangible assets, net | $ | 305,677 |  |  | $ | 306,439 |
(1) Accumulated amortization for complete technology includes immaterial amount of foreign currency translation adjustments for the complete technology acquired from the Vernalis acquisition. Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $16.9 million, $15.8 million, and $12.1 million was recognized for the years ended December 31, 2019 and 2018, and 2017, respectively. Estimated amortization expense for the years ending December 31, 2020 through 2024 is $14.1 million per year. For each of the years ended December 31, 2019, 2018, and 2017, there was no material impairment of intangible assets with finite lives. Accrued liabilities consist of the following (in thousands):
| December 31, |  |
| 2019 |  | 2018
Compensation | $ | 1,986 |  |  | $ | 4,045 |
Legal | 1,135 |  |  | 942 |
Amounts owed to former licensees | 381 |  |  | 428 |
Royalties owed to third parties | — |  |  | 1,025 |
Payments due to broker for share repurchases | — |  |  | 4,613 |
Return reserve | 3,027 |  |  | 3,590 |
Restructuring | — |  |  | 1,093 |
Current operating lease liabilities | 1,242 |  |  | — |
Other | 2,065 |  |  | 3,464 |
| $ | 9,836 |  |  | $ | 19,200 |
Contingent liabilities: In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones. In connection with the acquisition of Crystal in October 2017, we entered into contingent liabilities based on achievement of certain research and business milestones as well as certain revenue goal. See “Note (4), Business Combinations” for more information. The following table summarizes rollfoward of contingent liabilities as of December 2019 and 2018 (in thousands):
| December 31, 2017 | Payments | Fair Value Adjustment |  |  | December 31, 2018 | Payments | Fair Value Adjustment | Repurchases | December 31, 2019
Cydex | $ | 1,589 |  | $ | (25) |  | $ | (1,050) |  |  |  | $ | 514 |  | $ | (50) |  | $ | (116) |  | $ | — |  | $ | 348 |
Metabasis | 3,971 |  | (3,860) |  | 5,440 |  |  |  | 5,551 |  | — |  | 904 |  | (520) |  | 5,935 |
Crystal | 8,401 |  | (1,000) |  | (924) |  |  |  | 6,477 |  | (3,000) |  | (818) |  | — |  | 2,659 |
Total | $ | 13,961 |  | $ | (4,885) |  | $ | 3,466 |  |  |  | $ | 12,542 |  | $ | (3,050) |  | $ | (30) |  | $ | (520) |  | $ | 8,942 |

X
- Definition Other Balance Sheet Details [Abstract] + References No definition available. + Details
Name: | lgnd_OtherBalanceSheetDetailsAbstract
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration